Loading...
•
Dec 31, 2021
Evelo Q4 2021 Earnings Report
Evelo Biosciences reported financial results for Q4 2021 and business highlights.
Key Takeaways
Evelo Biosciences reported a net loss of $28.7 million for the fourth quarter of 2021, with R&D expenses at $18.9 million and G&A expenses at $8.7 million. Cash and cash equivalents were $68.4 million as of December 31, 2021.
Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022.
Positive data reported on faster release capsule.
Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout.
Statistically significant reductions in the Psoriasis Area and Severity Index (PASI) score were observed in two of the three cohorts treated with EDP1815
Evelo
Evelo
Forward Guidance
Evelo intends to move towards registration trials in psoriasis following the completion of meetings with health authorities this year. Topline data from 16-weeks of dosing in the Phase 2 trial in atopic dermatitis is anticipated in 1H 2023. Interim data from Phase 1b trial for EDP1867 is expected in early 2Q 2022. Initiation of clinical development of first extracellular vesicle (EV) anticipated in 3Q 2022. Phase 2 data from a cohort of patients with psoriasis expected in 2H 2023
Positive Outlook
- Move towards registration trials in psoriasis following the completion of meetings with health authorities this year
- Topline data from 16-weeks of dosing in the Phase 2 trial in atopic dermatitis is anticipated in 1H 2023
- Interim data from Phase 1b trial for EDP1867 is expected in early 2Q 2022
- Initiation of clinical development of first extracellular vesicle (EV) anticipated in 3Q 2022
- Phase 2 data from a cohort of patients with psoriasis expected in 2H 2023